Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors

Patent No. EP2252289 (titled "Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors") was filed by Mitsubishi Tanabe Pharma on Jan 16, 2009. The application was issued on Oct 23, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ELKINGTON AND FIFEJul 22, 2020-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2252289

MITSUBISHI TANABE PHARMA
Application Number
EP09701670A
Filing Date
Jan 16, 2009
Status
Revoked
Jan 17, 2025
Publication Date
Oct 23, 2019